Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

This study has been completed.
Sponsor:
Collaborators:
Kyungpook National University
Daegu Catholic University Medical Center
DongGuk University
Pusan National University Hospital
Yeungnam University
Information provided by (Responsible Party):
Jang Byoung Kuk, Keimyung University Dongsan Medical Center
ClinicalTrials.gov Identifier:
NCT01732367
First received: November 19, 2012
Last updated: October 27, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)